GSK Files Promacta NDA For Short-Term Treatment Of ITP
This article was originally published in The Pink Sheet Daily
Executive Summary
If approved, drug will be first oral platelet growth factor for idiopathic thrombocytopenic purpura.
You may also be interested in...
FDA’s ODAC Concerned About Off-Label, Long-Term Promacta Use
GlaxoSmithKline’s ITP treatment gets panel review May 30 onsite at ASCO.
FDA’s ODAC Concerned About Off-Label, Long-Term Promacta Use
GlaxoSmithKline’s ITP treatment gets panel review May 30 onsite at ASCO.
Promacta, Doribax Applications Get Advisory Committee Reviews
Amgen’s Enbrel will also be reviewed for a pediatric psoriasis indication.